ISSN: 0443-511
e-ISSN: 2448-5667
Usuario/a
Idioma
Herramientas del artículo
Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión)
Tamaño de fuente

Open Journal Systems

Protocolo de Atención Integral: hipertensión arterial sistémica / Integrated Care Protocol: Hypertension

Gabriela Borrayo-Sánchez, Martín Rosas-Peralta, María Cristina Guerrero-León, Héctor Galván-Oseguera, Adolfo Chávez-Mendoza, Juana Marlen Ruiz-Batalla, Joaquín Vargas-Peñafiel, Virginia Rosario Cortés-Casimiro, Nancy Xochitl Ramírez-Cruz, Carlos Alberto Soto-Chávez, Juan Luis Gerardo Durán-Arenas, Ricardo Avilés-Hernández, Víctor Hugo Borja-Aburto, Célida Duque-Molina

Resumen


Resumen

Introducción: la hipertensión arterial sistémica (HAS) es el factor de riesgo cardiovascular más común y es responsable de complicaciones como evento cerebrovascular, insuficiencia cardiaca, infarto agudo de miocardio, insuficiencia renal, arritmias y ceguera. Alrededor del 30% de la población adulta mayor de 20 años es portadora. El 40% de los portadores ignoran padecerla ya que su inicio generalmente es asintomático. Desafortunadamente de los que ya se saben hipertensos solo la mitad toma tratamiento farmacológico y de estos, tan solo la mitad logra cifras de control (< 140/90 mmHg). Durante varias décadas no se ha logrado de forma contundente modificar la historia natural de esta enfermedad pese al avance fármaco terapéutico. El Instituto Mexicano del Seguro Social, lanza la iniciativa de los Protocolos de Atención Integral (PAI) de las principales enfermedades. En el presente protocolo se muestra cómo se concatenan los tres niveles de atención médica, el papel de cada uno de los integrantes del equipo multidisciplinario para la atención médica, incluyendo: médico, enfermera, trabajo social, psicólogo, nutricionista, entre otros y, la coparticipación del paciente. Se presentan los principales cambios en criterios diagnósticos, medición de la presión arterial dentro y fuera de consultorio, terapéutica farmacológica (monoterapia, terapia dual y terapia triple), no farmacológica y seguimiento. El Abordaje diagnóstico-terapéutico usando algoritmos, así como también el abordaje diagnóstico de la hipertensión secundaria y formas especiales de hipertensión tales como en el embarazo, crisis hipertensivas, hipertensión en el adulto mayor, pacientes isquémicos o con nefropatía.

 

Abstract

Background: Hypertension is the most common cardiovascular risk factor that is responsible for complications such as cerebrovascular events, heart failure, acute myocardial infarction, kidney failure, arrhythmias and blindness. About 30% of the adult population older than 20 years is a carrier. 40% of carriers are unaware of suffering from it since its onset is generally asymptomatic. Unfortunately, of those who are already known to be hypertensive, only half take drug treatment and of these, only half achieve control figures (<14/90 mmHg). For several decades it has not been possible to forcefully modify the natural history of this disease despite the advancement of therapeutic drugs. The Mexican Institute of Social Security launches the initiative of the Integrated Care Protocols (PAI) of the main diseases. This protocol shows how the three levels of medical care are concatenated, the role of each of the members of the multidisciplinary team for medical care, including: doctor, nurse, social work, psychologist, nutritionist, among others and, to patient sharing. The main changes in diagnostic criteria, in-office and out-of-office blood pressure measurement, drug therapy (monotherapy, dual therapy and triple therapy) and non-drug therapy, and follow-up are presented. The diagnostic-therapeutic approach using algorithm as well as the diagnostic approach to secondary hypertension and special forms of hypertension such as in pregnancy, hypertensive crisis, hypertension in the elderly, ischemic or nephropathy patients.

 


Palabras clave


Hipertensión; Prevención; Diagnóstico; Tratamiento Integral / Hypertension; Prevention; Diagnosis; Treatment

Texto completo:

PDF

Referencias


 

 

Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 2009 Apr 28;6(4): e1000058. doi: 10.1371/journal.pmed.1000058.

 

INEGI 2020. Causas de Mortalidad. COMUNICADO DE PRENSA NÚM. 592/21 28 DE OCTUBRE DE 2020.

 

El Informe de Labores y Programa de Actividades 2020-2021 (ILPA). Primera edición. Página 470. http://www.imss.gob. mx/conoce-al-imss/informes-estadisticas.

 

Rosas PM, Palomo-Piñón S, Borrayo-Sánchez G, MadridMiller A, Almeida-Gutiérrez E, Galván-Oseguera H, et al. Consenso de Hipertension Arterial en Mexico. Rev Med Inst Mex Seguro Soc. 2016;54 Supl 1:S6-51. Spanish. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27284844/.

 

Rosas PM, Borrayo-Sánchez G, Santiago-López J, RamírezArias E, García-Méndez R, Borja-Aburto VH, et al. What is new in Hypertension of Mexico 2018? -Impact of the new classification of high blood pressure in adults from American College of Cardiology/American Heart Association (ACC/ AHA). Ann Clin Hypertens. 2018; 2: 024-030. https://doi.org/ 10.29328/journal.ach.1001008.

 

Reboussin DM, Allen NB, Griswold ME, Guallar E, Hong Y, Lackland DT, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Sep;72(3):e33. doi: 10.1161/HYP.0000000000000080.

 

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. ACC/AHA/AAPA/ABC/ ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):2199-2269. doi: 10.1016/j. jacc.2017.11.005.

 

Williams Bryan, Mancia Giuseppe, Spiering Wilko, Agabiti Rosei Enrico, Azizi Michel, Burnier Michel, Clement Denis L, Coca Antonio, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal, Volume 39, Issue 33, 01 September 2018, Pages 3021–3104, https://doi. org/10.1093/eurheartj/ehy339.

 

NICE guidelines 2019. Hypertension in pregnancy: diagnosis and management. Published: 25 June 2019. Acceso a página junio 25, 2019. Disponible en: https://www.nice.org. uk/guidance/ng133/resources/hypertension-in-pregnancydiagnosis-and-management-pdf-66141717671365.

 

Flegal KM, Kit BK, Orpana H, Graubard BI. Association of allcause mortality with overweight and obesity using standard body mass index categories: a systematic review and metaanalysis. JAMA. 2013 Jan 2;309(1):71-82. doi: 10.1001/ jama.2012.113905.

 

Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015 Mar 13;116(6):991- 1006. doi: 10.1161/CIRCRESAHA.116.305697.

 

Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright JT Jr, et al. Potential US Population Impact of the 2017 ACC/ AHA High Blood Pressure Guideline. Circulation. 2018 Jan 9;137(2):109-118. doi: 10.1161/CIRCULATIONAHA.117.032582.

 

Doumas M., Bakris G.L. (2019) Management of Hypertension in Diabetes Mellitus. In: Papademetriou V., Andreadis E., Geladari C. (eds) Management of Hypertension. Springer, Cham.

 

PROY-NOM-030-SSA2-2017, Para la prevención, detección, diagnóstico, tratamiento y control de la hipertensión arterial sistémica. DOF 19/04/2017.

 

Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: Core Curriculum. Am J Kidney Dis 2019.74(1):120-131. Published online March 19, 2019. doi: 10.1038/nm1267.

 

Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and metaanalysis. Lancet. 2016 Jan 30;387(10017):435-43. doi: 10.1016/S0140-6736(15)00805-3.

 

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of andomized trials. J Hypertens. 2016 Apr;34(4):613-22. doi: 10.1097/HJH.0000000000000881.

 

Volpe M, Tocci G, de la Sierra A, Kreutz R, Laurent S, Manolis AJ, et al. Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform. High Blood Press Cardiovasc Prev. 2017 Dec;24(4):463-472. doi: 10.1007/s40292-017-0239-7.

 

Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, et al. Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children Canadian Journal of Cardiology, 2018; 34(5): 506 – 525. doi: 10.1016/j. cjca.2018.02.022.

 

National Institutes of Health, National Heart, Lung, and Blood Institute. Your guide to lowering your blood pressure with DASH. NIH Publication 2006.

 

SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939.

 

Van den Born BH, Lip GYH, Brguljan-Hitij J, Cremer A, Segura J, Morales E, et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):37-46. doi: 10.1093/ehjcvp/pvy032.

 

Falaschetti E, Rockwood K, Mitnitski A, Thijs L, Beckett N, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the Hypertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015 Apr 9;13:78. doi: 10.1186/s12916-015-0328-1.

 

Mills KT, Bundy JD, Kelly TN, Redd JE, Kearney PM Reynolds K, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Populattions Based Studies From 90 Contries. Circulation 2016.134(6):441-50. doi: 10.1161/CIRCULATIONAHA.115.018912.

 

Instituto Mexicano del Seguro Social. Algoritmos terapéuticos para la atención de la Hipertensión Arterial Sistémica, Dislipidemias, Diabetes Mellitus 2 y Enfermedades Infecciosas. Actualización a octubre 2020.

 

 


Enlaces refback

  • No hay ningún enlace refback.